ClinicalTrials.gg
Active, not recruitingNCT07407595PACEUpdated Feb 13, 2026

Effect of Anticipated Pain on Corticospinal Excitability

An interventional study of Pain Expectation Manipulation in Nocebo Effect and Kinesiophobia, sponsored by Universite du Littoral Cote d'Opale. Active, not recruiting at 1 site in France. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Universite du Littoral Cote d'Opale · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Kinesiophobia with a site in France — 4 open to participants now, 5 under way, none of them phase 3. Kinesiophobia · France.

Started
2026
with 2 others
No phase
8 of 11
3 open now
Registered
8th of 11
by date
Lead sponsor
3 of 11
Universite du Littoral Cote d'Opale

Among the 11 studies in Kinesiophobia with a site in France, this one is one of 3 that started in 2026, is one of 8 with no phase, and was the 8th registered.

Kinesiophobia

287 studies on the registry are indexed under Kinesiophobia; 92 are open to participants now.

Browse Kinesiophobia studies →

Open to participants now

4 of the 11 studies in Kinesiophobia with a site in France are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 43 Kinesiophobia studies recruiting now, 13 (30%) set no upper age limit and 24 (56%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Kinesiophobia with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to investigate how the anticipation of pain, in the absence of real pain, affects the excitability of the corticospinal pathway. Corticospinal excitability reflects how responsive the motor areas of the brain are when sending signals to muscles.

In this study, healthy adult participants will be randomly assigned to one of two groups. Both groups will receive the application of an inert cream on the forearm. Participants in the experimental group will be told that the cream may cause pain, while participants in the control group will be informed that the cream is completely inactive. In reality, the cream has no physical effect in either group. This design allows the researchers to isolate the effect of pain anticipation (a nocebo effect) without exposing participants to actual pain.

Corticospinal excitability will be measured using transcranial magnetic stimulation (TMS), a non-invasive technique that stimulates the motor cortex to assess brain-to-muscle communication. Measurements will be taken before and after the application of the cream.

In addition, psychological factors related to catastrophizing and fear of movement will be assessed using validated questionnaires, and physiological responses associated with stress will be measured through heart rate variability.

The main question this study aims to answer is whether anticipating pain, even without experiencing real pain, alters corticospinal excitability, and whether this effect is influenced by fear of movement and catastrophizing. By improving our understanding of how pain-related expectations affect brain function, this research may contribute to better strategies for preventing maladaptive motor changes associated with chronic pain.

Read the detailed description

Pain-related processes involve not only sensory inputs but also cognitive and emotional factors such as expectation, fear, and anticipation. Anticipating pain can influence motor behavior and emotional responses even in the absence of actual nociceptive stimulation. These anticipatory mechanisms are thought to contribute to maladaptive motor adaptations and may play a role in the development and maintenance of chronic pain conditions. However, the neurophysiological effects of pain anticipation, independently of real pain, remain insufficiently understood.

The aim of this study is to examine the effect of pain anticipation on corticospinal excitability, a neurophysiological marker of motor cortex responsiveness and brain-to-muscle communication. Corticospinal excitability is assessed using transcranial magnetic stimulation (TMS) applied over the primary motor cortex. This non-invasive technique allows evaluation of motor pathway function through the elicitation of motor evoked potentials recorded from a target hand muscle.

To specifically investigate anticipation-related effects, the study uses an experimental paradigm designed to manipulate pain expectancy without inducing actual pain. In addition to neurophysiological measures, psychological factors related to fear of movement and physiological markers of autonomic nervous system activity are considered, as they may influence the impact of pain anticipation on motor system function.

Procedures :

After providing informed consent, participants take part in a single experimental session conducted in a laboratory setting. The session begins with baseline assessments designed to characterize neurophysiological, psychological, and autonomic parameters prior to any experimental manipulation.

Participants first complete self-report questionnaires assessing fear of movement, catastrophizing and pain-related avoidance beliefs (EKT-CF, PCS-CF and FACS-CF).

Baseline measurements of corticospinal excitability are then obtained using transcranial magnetic stimulation (TMS) applied over the primary motor cortex. The TMS will be used to establish the input-output (I/O) curves. Stimuli of variable intensity between the threshold value (or MT for motor threshold) and the maximum will be delivered. In total, about ten stimulation intensities will be tested, and for each stimulation intensity, ten stimuli will be delivered, allowing then to calculate the average of the MEPs in order to draw the I/O curves of each participant. The resulting motor evoked potentials to characterize global corticospinal responsiveness. As recalled by national and international recommendations, TMS is a noninvasive and painless technique whose use in the scientific literature is extremely abundant.

In parallel, baseline autonomic activity is recorded using heart rate variability measures.

Following baseline assessments, participants are randomly assigned to either an experimental group or a control group. In both groups, an inert cream is applied to a predefined area of the forearm. The manipulation differs only in the information provided to participants. Those assigned to the experimental group are informed that the cream is expected to induce painful sensations (such as burning or tingling) after an approximate delay of ten minutes, with the pain progressively increasing in intensity over time, whereas participants in the control group are informed that the cream is inactive and will not produce any sensation. In reality, the same inert cream is used for all participants. This procedure is designed to induce anticipation of pain in the experimental group without exposing participants to actual nociceptive stimulation.

Immediately after the application of the cream and the expectancy manipulation, corticospinal excitability is reassessed using the same TMS procedures as at baseline. Measurements are repeated to examine changes in motor system excitability associated with pain anticipation. Autonomic nervous system activity continues to be monitored throughout this phase.

To reinforce the anticipatory context, additional TMS measurements, using the same procedures, are performed around the time when participants in the experimental group are led to expect the onset of pain (approximatively 10 minutes after cream application). This allows assessment of corticospinal excitability during heightened anticipation, independently of any real sensory input.

At the end of the experimental session, participants are asked to report their perceived pain and level of apprehension during the study. A full debriefing is then conducted, during which the true purpose of the study and the use of expectancy manipulation are explained. Participants are given the opportunity to ask questions and withdraw their data if they wish.

The duration of the experimental session is estimated at 1h30min, distributed as follows: Information, eligibility and consent collection, questionnaires completion : 20 minutes; preparation of the experiment (installation of the electrodes, setting of the devices: 10 minutes; recordings: 1 hour).

03

Conditions studied

  • Nocebo Effect
  • Kinesiophobia

Browse trials for

Keywords

  • Pain anticipation
  • Nocebo effect
  • Kinesiophobia
  • Corticospinal excitability
  • Transcranial magnetic stimulation
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 65 years.
  • No current pain at the time of inclusion and no pain episode or injury associated with pain within the past 3 months.
  • Ability to understand spoken and written French sufficient to follow study procedures.
  • Written obtained prior to participation.
  • Subjects affiliated with or receiving social security benefits

Exclusion criteria

Exclusion Criteria:

  • History of psychiatric disorders (including intellectual disability or severe cognitive, behavioral, or affective impairment) that could interfere with understanding the study or providing .
  • History of neurological disorders, including epilepsy, stroke, brain or spinal cord surgery, or any neurological disease affecting motor or sensory function.

Inability to provide informed consent (e.g., dementia, significant hearing impairment, insufficient language proficiency).

  • Any pain condition within the past 3 months, regardless of origin.
  • Recent musculoskeletal injury or surgery within the past 3 months.
  • to transcranial magnetic stimulation (TMS), including a history of epilepsy or the presence of intracranial metallic objects, cochlear implants, or other non-removable metallic implants in or near the head.
  • Use of analgesic or psychotropic medications.
  • Individuals under legal guardianship or curatorship.
  • Pregnant or breastfeeding women.
  • Presence of a cardiac pacemaker or other implanted electronic medical device.
  • Known allergy or history of skin reaction to any component of the inert cream used in the study (Medicafarm® Neutre Premium Longue Glisse).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Other
    Control Group - Inert Cream (Neutral Information)

    Participants in this control arm receive the application of an inert cream on the forearm. They are informed that the cream is inactive and will not produce any sensation or effect. This arm serves as a control condition for the manipulation of pain anticipation, with identical procedures and measurements as the experimental arm, except for the information provided about the expected effects of the cream.

    Other: Pain Expectation Manipulation

  • Experimental
    Experimental Group - Inert Cream (Pain Expectation Information)

    Participants in this experimental arm receive the application of an inert cream on the forearm. They are informed that the cream is expected to induce painful sensations after a delay, with pain gradually increasing in intensity over time. This information is used to induce anticipation of pain without actual nociceptive stimulation. All procedures and measurements are identical to those of the control arm, except for the information provided about the expected effects of the cream.

    Other: Pain Expectation Manipulation

Interventions

  • OtherPain Expectation Manipulation

    The intervention consists of an information-based manipulation designed to induce (or not induce) anticipation of pain. Participants receive the application of an inert cream on the forearm. Depending on group assignment, participants are informed either that the cream is inactive and will not produce any sensation, or that it is expected to produce painful sensations such as burning, stinging, or tingling, with onset approximately 10 minutes after application and a gradual increase in intensity over time, reaching a moderate to strong level of perceived pain. The cream itself has no active or sensory effects in any group. This intervention allows manipulation of pain expectation without inducing actual nociceptive stimulation.

06

What researchers measure

Primary outcomes

  1. Change from baseline in corticospinal excitability

    Corticospinal excitability will be assessed using transcranial magnetic stimulation (TMS) applied over the primary motor cortex. Single magnetic pulses of increasing intensity will be delivered to construct input-output (I/O) recruitment curves for each participant at baseline, immediately after cream application, and 10 minutes after cream application. Stimulation intensity will be increased in 3-5% steps, and 10 stimuli will be delivered at each intensity level. Motor evoked potentials elicited by TMS will be recorded using surface electromyography from the first dorsal interosseous muscle of the hand. I/O curves will be modeled using a Boltzmann sigmoidal function, and the slope, plateau, and S50 parameters will be extracted. Changes in corticospinal excitability will be compared between groups across these time points.

    Time frame: During single session: baseline (pre-cream application), immediately post-cream application, and 10 minutes post-cream application

Secondary outcomes

  1. Fear-avoidance beliefs related to pain

    Fear-avoidance beliefs will be assessed using the French-Canadian version Fear-Avoidance Components Scale (FACS-FR/CF), a self-report questionnaire designed to measure cognitive, emotional, and behavioral components of fear-avoidance related to pain. The scale includes items assessing pain-related fear, anxiety, catastrophic thinking, and avoidance behaviors. The FACS-FR/CF consists of 20 items rated on a Likert scale from 0 (strongly disagree) to 5 (strongly agree), yielding a total score ranging from 0 to 100. Higher scores indicate greater levels of fear-avoidance. Severity levels are commonly interpreted as subclinical (0-20), mild (21-40), moderate (41-60), severe (61-80), and extreme (81-100).

    Time frame: Baseline

  2. Kinesiophobia

    Kinesiophobia will be assessed using the French-Canadian version of the Tampa Kinesiophobia Questionnaire (EKT-CF). It takes the form of a self-reported questionnaire of 17 items using a Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree), with an acceptable degree of internal consistency (Cronbach's alpha = 0.71), satisfactory construct validity, and high sensitivity to change (intra-class correlation coefficient \> 0.7). The total score is obtained by adding the value of the responses and is between 17 and 68. The value of 40/68 is considered as the threshold value at which kinesiophobia becomes significant.

    Time frame: Baseline

  3. Change in heart rate variability from Baseline

    Heart rate variability (HRV) will be assessed as an index of autonomic nervous system activity. R-R intervals will be continuously recorded throughout the single study session, starting with the baseline resting period and continuing through completion of the TMS procedure. Time-domain HRV parameters (e.g., mean heart rate, RMSSD) will be derived from the continuous recording to evaluate autonomic responses associated with pain anticipation.

    Time frame: During the single study session, from the baseline resting period through completion of the TMS procedure (up to 60 minutes)

  4. Pain catastrophizing related to pain

    Pain catastrophizing will be assessed using the French-Canadian version of the Pain Catastrophizing Scale (PCS-CF), a self-report questionnaire designed to measure catastrophic thoughts related to pain. The PCS-CF includes 13 items rated on a Likert scale from 0 ("not at all") to 4 ("all the time"), covering three dimensions: rumination, magnification, and helplessness. Item scores are summed to yield a total score ranging from 0 to 52, with higher scores indicating greater pain catastrophizing. A total score ≥30 has been proposed to identify clinically relevant levels of pain catastrophizing.

    Time frame: Baseline

  5. Change from baseline in intracortical inhibition and facilitation (SICI and SICF)

    Intracortical inhibitory and facilitatory circuits will be assessed using paired-pulse transcranial magnetic stimulation applied over the primary motor cortex. A subthreshold conditioning stimulus (80% RMT) will be followed by a suprathreshold (120% RMT) test stimulus to quantify short-interval intracortical inhibition (SICI), whereas paired-pulse stimulation at facilitative interstimulus intervals will be used to quantify short-interval intracortical facilitation (SICF). These measures will be obtained for each participant at baseline, immediately after cream application, and 10 minutes after cream application. Motor evoked potentials elicited by TMS will be recorded using surface electromyography from the first dorsal interosseous muscle of the hand. SICI and SICF will be expressed as the ratio of conditioned to unconditioned MEP amplitude (e.g., % of test MEP).

    Time frame: During single session: baseline (pre-cream application), immediately post-cream application, and 10 minutes post-cream application

Other outcomes

  1. Brief Pain Inventory

    Current pain status will be assessed using the Brief Pain Inventory, French version (BPI-FR), a self-report questionnaire widely used to evaluate pain severity and pain-related interference with daily activities. In this study, the BPI-FR is used to confirm the absence of clinically relevant pain at inclusion. The questionnaire includes 11 items: four items assessing pain intensity (worst, least, average, and current pain) and seven items assessing the extent to which pain interferes with daily functioning, mood, sleep, and social activities. Pain intensity and interference are rated on numeric scales ranging from 0 (no pain or no interference) to 10 (worst imaginable pain or complete interference). Higher scores indicate greater pain severity and impact.

    Time frame: Baseline

  2. Change from baseline in perceived apprehension

    Perceived apprehension related to the experimental context will be assessed using a 0-10 numeric rating scale, where 0 indicates "no apprehension at all" and 10 indicates "the highest apprehension imaginable." Participants will rate their apprehension at predefined time points before and after the expectancy manipulation in order to evaluate changes in apprehension associated with the experimental instructions and procedures.

    Time frame: During the single study session: baseline (pre-cream application), immediately post-cream application, and 10 minutes post-cream application

  3. Change from baseline in perceived pain intensity

    Perceived pain intensity will be assessed using a 0-10 numeric rating scale, where 0 indicates "no pain" and 10 indicates "the worst pain imaginable." Participants will rate perceived pain intensity at predefined time points before and after the expectancy manipulation in order to support the credibility of the experimental instructions and to explore whether pain anticipation may be associated with a perceived experience of pain in the absence of actual nociceptive stimulation.

    Time frame: During the single study session: baseline (pre-cream application), immediately post-cream application, and 10 minutes post-cream application

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jul 2026, 5 months after the start.

Of 133 non-industry interventional studies with no phase under Kinesiophobia, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 5 months is below that.

Counting every sponsor, half of 133 studies reached it within 8 months; a quarter within 4 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2025
First posted
Feb 12, 2026
StartActual
Feb 12, 2026
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07407595
Lead sponsor
Universite du Littoral Cote d'Opale
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Feb 12, 2026
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Feb 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion